196 related articles for article (PubMed ID: 32971350)
1. Views of healthcare professionals about the role of active monitoring in the management of ductal carcinoma in situ (DCIS): Qualitative interview study.
Nickel B; McCaffery K; Houssami N; Jansen J; Saunders C; Spillane A; Rutherford C; Dixon A; Barratt A; Stuart K; Robertson G; Hersch J
Breast; 2020 Dec; 54():99-105. PubMed ID: 32971350
[TBL] [Abstract][Full Text] [Related]
2. Women's views about current and future management of Ductal Carcinoma in Situ (DCIS): A mixed-methods study.
Nickel B; McCaffery K; Jansen J; Barratt A; Houssami N; Saunders C; Spillane A; Rutherford C; Stuart K; Robertson G; Dixon A; Hersch J
PLoS One; 2023; 18(7):e0288972. PubMed ID: 37478123
[TBL] [Abstract][Full Text] [Related]
3. How different terminology for ductal carcinoma in situ (DCIS) impacts women's concern and management preferences: A qualitative study.
Nickel B; Barratt A; Hersch J; Moynihan R; Irwig L; McCaffery K
Breast; 2015 Oct; 24(5):673-9. PubMed ID: 26376460
[TBL] [Abstract][Full Text] [Related]
4. Identifying opportunities to support patient-centred care for ductal carcinoma in situ: qualitative interviews with clinicians.
Nyhof BB; Wright FC; Look Hong NJ; Groot G; Helyer L; Meiers P; Quan ML; Baxter NN; Urquhart R; Warburton R; Gagliardi AR
BMC Cancer; 2020 Apr; 20(1):364. PubMed ID: 32354355
[TBL] [Abstract][Full Text] [Related]
5. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
6. How different terminology for ductal carcinoma in situ impacts women's concern and treatment preferences: a randomised comparison within a national community survey.
McCaffery K; Nickel B; Moynihan R; Hersch J; Teixeira-Pinto A; Irwig L; Barratt A
BMJ Open; 2015 Nov; 5(11):e008094. PubMed ID: 26525720
[TBL] [Abstract][Full Text] [Related]
7. Valuing preferences for treating screen detected ductal carcinoma in situ.
Bromley HL; Mann GB; Petrie D; Nickson C; Rea D; Roberts TE
Eur J Cancer; 2019 Dec; 123():130-137. PubMed ID: 31689678
[TBL] [Abstract][Full Text] [Related]
8. Perceptions of ductal carcinoma in situ (DCIS) among UK health professionals.
Kennedy F; Harcourt D; Rumsey N
Breast; 2009 Apr; 18(2):89-93. PubMed ID: 19231188
[TBL] [Abstract][Full Text] [Related]
9. Recommendations to improve patient-centred care for ductal carcinoma in situ: Qualitative focus groups with women.
Nyhof BB; Wright FC; Look Hong NJ; Groot G; Helyer L; Meiers P; Quan ML; Baxter NN; Urquhart R; Warburton R; Gagliardi AR
Health Expect; 2020 Feb; 23(1):106-114. PubMed ID: 31532871
[TBL] [Abstract][Full Text] [Related]
10. The challenge of being diagnosed and treated for ductal carcinoma in situ (DCIS).
Kennedy F; Harcourt D; Rumsey N
Eur J Oncol Nurs; 2008 Apr; 12(2):103-11. PubMed ID: 18023255
[TBL] [Abstract][Full Text] [Related]
11. Personalizing the Treatment of Women with Ductal Carcinoma In Situ (DCIS) Using the DCIS Score: A Qualitative Study on Score Use.
O'Brien MA; Paszat L; Makuwaza T; Fong C; Rakovitch E
Curr Oncol; 2024 Feb; 31(2):975-986. PubMed ID: 38392067
[TBL] [Abstract][Full Text] [Related]
12. Addressing overtreatment of screen detected DCIS; the LORIS trial.
Francis A; Thomas J; Fallowfield L; Wallis M; Bartlett JM; Brookes C; Roberts T; Pirrie S; Gaunt C; Young J; Billingham L; Dodwell D; Hanby A; Pinder SE; Evans A; Reed M; Jenkins V; Matthews L; Wilcox M; Fairbrother P; Bowden S; Rea D
Eur J Cancer; 2015 Nov; 51(16):2296-303. PubMed ID: 26296293
[TBL] [Abstract][Full Text] [Related]
13. Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
Rosso KJ; Weiss A; Thompson AM
Surg Oncol Clin N Am; 2018 Jan; 27(1):69-80. PubMed ID: 29132566
[TBL] [Abstract][Full Text] [Related]
14. What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?
Mercieca-Bebber R; King MT; Boxer MM; Spillane A; Winters ZE; Butow PN; McPherson J; Rutherford C
Breast Cancer; 2017 Sep; 24(5):720-729. PubMed ID: 28247220
[TBL] [Abstract][Full Text] [Related]
15. Non-surgical treatment for ductal carcinoma in situ of the breasts - a prospective study on patient's perspective.
Co M; Lee A; Kwong A
Cancer Treat Res Commun; 2021; 26():100241. PubMed ID: 33340904
[TBL] [Abstract][Full Text] [Related]
16. Avoiding Overtreatment of Ductal Carcinoma in situ.
van der Borden CL; Stoffers S; Lips EH; Wesseling J
Trends Cancer; 2019 Jul; 5(7):391-393. PubMed ID: 31311652
[TBL] [Abstract][Full Text] [Related]
17. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).
Hwang ES; Hyslop T; Lynch T; Frank E; Pinto D; Basila D; Collyar D; Bennett A; Kaplan C; Rosenberg S; Thompson A; Weiss A; Partridge A
BMJ Open; 2019 Mar; 9(3):e026797. PubMed ID: 30862637
[TBL] [Abstract][Full Text] [Related]
18. The management of women with ductal carcinoma in situ of the breast in Australia and New Zealand between 2007 and 2016.
Omling S; Houssami N; McGeechan K; Zackrisson S; Jacklyn G; Walters D; Barratt A; Farber R
ANZ J Surg; 2021 Sep; 91(9):1784-1791. PubMed ID: 34075674
[TBL] [Abstract][Full Text] [Related]
19. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M
Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE; Tryfonidis K; Slaets L; van Leeuwen-Stok AE; Skinner VP; Dif N; Pijnappel RM; Bijker N; Rutgers EJ; Wesseling J
Eur J Cancer; 2015 Aug; 51(12):1497-510. PubMed ID: 26025767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
